a developer of novel anti-cancer medicines
Industry Biotechnology
A.I.dvisor indicates that over the last year, NCNA has been closely correlated with PIRS. These tickers have moved in lockstep 95% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then PIRS could also see price increases.
Ticker / NAME | Correlation To NCNA | 1D Price Change % | ||
---|---|---|---|---|
NCNA | 100% | -1.25% | ||
PIRS - NCNA | 95% Closely correlated | -0.12% | ||
CDTX - NCNA | 93% Closely correlated | +3.35% | ||
NBY - NCNA | 92% Closely correlated | -8.67% | ||
WINT - NCNA | 92% Closely correlated | -6.24% | ||
RNAC - NCNA | 92% Closely correlated | +1.12% | ||
More |
Ticker / NAME | Correlation To NCNA | 1D Price Change % |
---|---|---|
NCNA | 100% | -1.25% |
NCNA (22 stocks) | 26% Poorly correlated | -2.84% |
cancer (82 stocks) | 18% Poorly correlated | -2.38% |
drugs (254 stocks) | 17% Poorly correlated | -1.72% |
biotechnology (238 stocks) | 14% Poorly correlated | -1.80% |
europe (179 stocks) | 11% Poorly correlated | -0.25% |